Piramal Healthcare to buy Canadian firm's assets

Superior Court of Quebec allowed the Interim Receiver to accept the binding offer

June 22, 2010 11:17 pm | Updated 11:17 pm IST - MUMBAI

Piramal Healthcare announced the signing of a definitive agreement to acquire Canada's BioSyntech's assets for a consideration of Canadian $3.9 million (about Rs. 17.65 crore).

BioSyntech is a medical device company specialising in the development, manufacturing and commercialisation of advanced biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery.

Piramal had subscribed to common shares of BioSyntech in 2005-06 which then constituted 17 per cent of its equity. By virtue of this investment, Piramal had exclusive rights for marketing, selling and distributing current and future products of BioSyntech for India and some neighbouring Asian markets.

BioSyntech was unable to raise further capital to fund its operations and to repay debt and as a result, it sought court protection under insolvency proceedings. Taking into consideration Piramal Health's interests in the projects of BioSyntech, the former made a binding offer and the Superior Court of Quebec (Canada) allowed the Interim Receiver to accept this offer.

Commenting on the transaction, Ajay Piramal, Chairman, Piramal Group, said “BST-Car Gel is a one-stage application that can be performed arthroscopically and is the only potential substitute available for knee replacement surgery. This treatment also promises to be significantly less expensive than current alternatives.”

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.